A carregar...
Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience
Mutations in the BRAF oncogene are found in 2–4% of all non-small cell lung cancer (NSCLC) patients. The most common activating mutation present within the BRAF oncogene is associated with valine substitution for glutamate at position 600 (V600E) within the BRAF kinase. BRAF-targeted therapies are e...
Na minha lista:
| Publicado no: | Ther Adv Respir Dis |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5941661/ https://ncbi.nlm.nih.gov/pubmed/29595366 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466618767611 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|